TY - JOUR T1 - Nirsevimab reduces medically attended RSV-associated lower respiratory tract infection and hospitalisations in healthy pre-term infants JF - Archives of disease in childhood - Education & practice edition JO - Arch Dis Child Educ Pract Ed DO - 10.1136/archdischild-2020-321141 SP - edpract-2020-321141 AU - Sarah Murphy Y1 - 2021/02/17 UR - http://ep.bmj.com/content/early/2021/02/16/archdischild-2020-321141.abstract N2 - Review ofGriffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020;383:415–25.Study design: Randomised clinical trial.Allocation and blinding: Nirsevimab: placebo, 2:1 ratio. Randomisation was stratified by hemisphere (northern or southern) and by age (≤3 months, >3 months to ≤6 months, or >6 months). Concealment was ensured by using an interactive web response system. Participants, carers and outcome observers were blinded to allocation.Setting: Multisite international clinical trial including 23 countries from both the northern and southern hemispheres.Patients: Healthy ex-premature (29 + 0 to 34 = 6 weeks) infants without current indication for palivizumab, and without bronchopulmonary dysplasia, liver, renal or cardiac impairment who were currently aged <1 year (8 months in EU) and entering their first bronchiolitis season.Intervention: Nirsevimab 50 mg intramuscularly or matching placebo, given once, 2 months before RSV season.OutcomesPrimary outcome: Clinically documented, PCR-proven, medically attended respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI).Secondary outcome: Hospitalisation for RSV … ER -